In clinical settings, treatment with the glucocorticoid receptor antagonist mifepristone in patients with hypercortisolism has led to improvements in both biochemical markers and imaging findings associated with NAFLD [65]. The gene discussed is NR3C1; the disease is metabolic dysfunction-associated steatotic liver disease.